SNSE senseibio.com: Enterprise Value to EBITDA Ratio

Graphic logo of Sensei Biotherapeutics, Inc. (SNSE)

Sensei Biotherapeutics (SNSE) develops personalized tumor vaccines, claiming pricing power due to its unique method of immune stimulation. However, a lack of sales and high innovation costs are leading to capital depletion. Meanwhile, antibody development remains independent of economic cycles. A retrospective of the share price with an EV/EBITDA ratio of 0.00 confirms the high macro-resilience of the business during the R&D stage.

Sensei Biotherapeutics Inc - SNSE Total Company Value to Operating Income Before Depreciation Ratio (period 11/23/2025 - 06/16/2026)

Summary analytical data breakdowns for senseibio.com (SNSE)

- stock price and consensus target price:
Stock Quotes Sensei Biotherapeutics, Inc.|SNSE - Average Forecast Price
- company stock capitalization data:
Market Valuation SNSE|SNSE - Value Adjusted for Debt and Cash
- business book valuation details:
Book Value per Share Sensei Biotherapeutics|SNSE - Book Valuation of Business|Market Value to Book Value Ratio senseibio.com|SNSE - Cumulative Company Assets
- debt and solvency information:
Debt to Equity Sensei Biotherapeutics|SNSE - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Ratio Sensei Biotherapeutics, Inc.|SNSE - Company Aggregate Debts|Debt to Book Capitalization Ratio SNSE|SNSE - Company Long-Term Indebtedness|Company Short-Term Debt Sensei Biotherapeutics|Quick Liquidity Indicator senseibio.com
- financial results and valuation multiples details:
SNSE - Annual Net Income|Future Profit Sensei Biotherapeutics|SNSE - Market Price to Net Income Ratio|Forward P/E Multiple Sensei Biotherapeutics, Inc.|SNSE - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple SNSE|SNSE - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Sensei Biotherapeutics|SNSE - Earnings per share for the trailing year|Quarterly EPS earnings growth senseibio.com|SNSE - Earnings growth in current year|Net earnings per share growth forecast for next year Sensei Biotherapeutics
Fundamental company analysis:SNSE (Sensei Bio)
Original product of Sensei Biotherapeutics Inc

Developing innovative cancer vaccines requires significant capital expenditures, making the business valuation sensitive to debt load and tax obligations. The EV/EBITDA ratio for Sensei Biotherapeutics (SNSE) reflects the relationship between the total enterprise value and operating profit before depreciation and amortization, allowing investors to assess the real value of assets relative to their ability to generate cash flow regardless of the financing structure.

Competitor analysis for Sensei Biotherapeutics

ImmunityBio Corp - Enterprise Value to EBITDA Ratio|Immunocore Corp (IMCR) - Company Value to EBITDA|JANX: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RCUS (arcusbio.com)|ZYME: EV/EBITDA Multiple|TNGX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Iovance|Enterprise Value to EBITDA Ratio Immatics Biotechnologies (IMTX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Xencor, Inc. (XNCR)|Enterprise Value to EBITDA Ratio compasstherapeutics.com CMPX|Replimune - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Lyell LYEL|IPHA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PYXS (Pyxis Oncology, Inc.) - Enterprise Value to Operating Income Before Depreciation|cgen.com (CGEN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA iobiotech.com (IOBT)|Enterprise Value to EBITDA Ratio STRO|INKT - Enterprise Value to EBITDA Multiple|Enterprise Value to EBITDA Ratio HOWL (Werewolf Therapeutics)|Enterprise Value to Operating Income Before Depreciation Ratio IMMX|EV/EBITDA Multiple ALXO (ALX Oncology)|Business Value to Operating Income Before Depreciation CUE|PDS Biotechnology Corp - EV/EBITDA Multiple|Company Value to EBITDA Sonnet BioTherapeutics|MAIA Biotechnology Inc (MAIA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Liminatus - Business Value to Operating Income Before Depreciation|LVTX (LAVA Therapeutics NV) - EV/EBITDA Multiple|EV/EBITDA Multiple nextcure.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Leap Therapeutics, Inc. (LPTX)|INTS: Company Value to Operating Income Before Depreciation Ratio|Synthetic Biologics - Enterprise Value to EBITDA Ratio|Gritstone bio Inc. (GRTS) - Company Value to EBITDA|KA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio neximmune.com NEXI|TSBX: EV/EBITDA Multiple|Company Value to EBITDA Vaccinex Inc. (VCNX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Harpoon Tx